| First Author | Barker JE | Year | 2005 |
| Journal | Exp Hematol | Volume | 33 |
| Issue | 10 | Pages | 1118-29 |
| PubMed ID | 16219534 | Mgi Jnum | J:102334 |
| Mgi Id | MGI:3607376 | Doi | 10.1016/j.exphem.2005.06.021 |
| Citation | Barker JE, et al. (2005) High incidence, early onset of histiocytic sarcomas in mice with Hertwig's anemia. Exp Hematol 33(10):1118-29 |
| abstractText | OBJECTIVE: Histiocytic sarcoma (HS) is a rare, rapidly disseminated, usually lethal tumor in humans. Treatment specific for HS has not been developed primarily due to deficiencies of appropriate animal models with high incidence/early onset. Mice with Hertwig's anemia (an/an) provide a potential model. METHODS: Here, we compare HS susceptibility in an/an and unaffected control mice maintained on three genetic backgrounds. As a potential therapeutic measure, genetically marked bone marrow is transplanted between high and low susceptibility animals. RESULTS: HS is detected earlier and the overall incidence is 15-fold higher in WBB6F1(F1)-an/an than in F1-+/?, B6-an/an and -+/? mice. Neither WB-an/an nor their normal WB-+/? littermates present with HS. Liver myelopoiesis and aneuploidy coexist with HS but the former is also rampant (33.7% incidence) in HS-free +/? and an/an mice. Marrow transplantation experiments provide evidence that (1) myelopoiesis is associated with HS and (2) early-onset/high-incidence HS is blocked by using late-onset F1-+/+ mice, as either donor or recipient. CONCLUSIONS: Homozygosity for an on an F1 genetic background is essential for high-incidence/early-onset HS; myelopoiesis and HS coexist; and therapeutic transplantation may be feasible. |
